NASDAQ:PYPD PolyPid (PYPD) Stock Price, News & Analysis $3.80 +0.04 (+1.06%) As of 11:58 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About PolyPid Stock (NASDAQ:PYPD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PolyPid alerts:Sign Up Key Stats Today's Range$3.75▼$3.8550-Day Range$2.54▼$3.8052-Week Range$2.30▼$4.42Volume34,314 shsAverage Volume234,681 shsMarket Capitalization$38.72 millionP/E RatioN/ADividend YieldN/APrice Target$11.80Consensus RatingBuy Company Overview PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Read More PolyPid Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScorePYPD MarketRank™: PolyPid scored higher than 47% of companies evaluated by MarketBeat, and ranked 564th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingPolyPid has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePolyPid has only been the subject of 3 research reports in the past 90 days.Read more about PolyPid's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PolyPid is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PolyPid is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPolyPid has a P/B Ratio of 5.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PolyPid's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.70% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 41.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPolyPid does not currently pay a dividend.Dividend GrowthPolyPid does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.70% of the float of PolyPid has been sold short.Short Interest Ratio / Days to CoverPolyPid has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in PolyPid has recently decreased by 41.62%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for PYPD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added PolyPid to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PolyPid insiders have not sold or bought any company stock.Percentage Held by Insiders24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 26.47% of the stock of PolyPid is held by institutions.Read more about PolyPid's insider trading history. Receive PYPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter. Email Address PYPD Stock News HeadlinesPYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent BenefitsJuly 16, 2025 | finance.yahoo.comPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketJuly 15, 2025 | finance.yahoo.comBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, who called Bitcoin’s breakout to $100K nearly to the day, says a lesser-known coin could be even bigger. It’s faster, cheaper, and backed by Google, Visa, and top VCs with over $200 million already invested.July 24 at 2:00 AM | Weiss Ratings (Ad)PolyPid Launches Long-Acting GLP-1 Delivery Platform for Diabetes MarketJuly 15, 2025 | tipranks.comPolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss MarketJuly 15, 2025 | globenewswire.comPolyPid Ltd. (NASDAQ:PYPD) Receives $11.80 Average PT from BrokeragesJuly 15, 2025 | americanbankingnews.comPolyPid (NASDAQ:PYPD) Upgraded by Wall Street Zen to "Hold" RatingJuly 14, 2025 | americanbankingnews.comPolyPid Ltd. (PYPD) Latest Stock News & Headlines - Yahoo FinanceJune 26, 2025 | finance.yahoo.comSee More Headlines PYPD Stock Analysis - Frequently Asked Questions How have PYPD shares performed this year? PolyPid's stock was trading at $3.04 on January 1st, 2025. Since then, PYPD shares have increased by 25.0% and is now trading at $3.80. How were PolyPid's earnings last quarter? PolyPid Ltd. (NASDAQ:PYPD) announced its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.10. Read the conference call transcript. When did PolyPid's stock split? PolyPid's stock reverse split on Thursday, September 21st 2023.The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did PolyPid IPO? PolyPid (PYPD) raised $50 million in an IPO on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers. How do I buy shares of PolyPid? Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PolyPid own? Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU). Company Calendar Last Earnings5/14/2025Today7/23/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:PYPD CIK1611842 Webwww.polypid.com Phone972-74-719-5700FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Price Target for PolyPid$11.80 High Price Target$14.00 Low Price Target$9.00 Potential Upside/Downside+213.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.02 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,069.37% Return on Assets-151.85% Debt Debt-to-Equity Ratio4.43 Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book5.01Miscellaneous Outstanding Shares10,190,000Free Float7,674,000Market Cap$38.31 million OptionableNo Data Beta1.32 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PYPD) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.